Adding intra-arterial clot-busting therapy to endovascular treatment for medium-vessel stroke

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

PEARL-MeVO randomizes 530 adults with acute ischemic stroke due to isolated medium vessel occlusion to receive either intra-arterial thrombolysis plus endovascular treatment or standard medical management alone in a 1:1 ratio. The trial is prospective, multicenter and open-label with blinded endpoint assessment (PROBE), enrolling patients treated within 6 hours or within 6–24 hours when perfusion imaging shows salvageable brain tissue. The primary outcome is the proportion of patients achieving a modified Rankin Scale score of 0–1 at 90 days, with safety and secondary functional outcomes also tracked. Imaging-based core and mismatch criteria and a baseline NIHSS ≥6 are used to select eligible patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Aged 18 years or older.
2. Clinical diagnosis of acute ischemic stroke.
3. CT angiography (CTA) or MR angiography (MRA) confirmed primary isolated medium vessel occlusion (i.e. an occlusion of the co-/non-dominant M2, the M3/M4 segment of the MCA, the A1/A2/A3 segment of the ACA, or the P1/P2/P3 segment of the PCA).
4. Baseline NIHSS ≥6.
5. Treatment (arterial puncture) can be initiated 5.1 Within 6 hours of last known well (LKW) OR 5.2 Within 6 to 24 hours of LKW AND evidence of salvageable brain tissue on CT perfusion or perfusion-diffusion MRI (ischemic core volume \<50mL, hypo-perfused tissue volume to ischemic core volume ratio \>1.4, mismatch volume \>10mL). Hypo-perfused tissue is defined as Tmax \>6s on CT perfusion or perfusion MRI. Ischemic core is defined as rCBF \<30% on CT perfusion or ADC \<620μm2/s on diffusion MRI.
6. Signed informed consent.

Exclusion Criteria:

1. Evidence of intracranial hemorrhage.
2. Pre-stroke mRS score ≥ 2.
3. Rapidly improving symptoms, in the judgment of the managing clinician that the improvement is likely to result in the patient having an NIHSS score of \<6 at randomization.
4. The intervention procedure is unlikely to be completed as assessed by the investigator.
5. Suspected cerebral vasculitis, septic embolization, or vascular occlusion due to infective endocarditis.
6. Suspected arterial dissection.
7. Severe allergy to contrast agents (non-mild rash allergy) or absolute contraindication to iodine contrast.
8. Known genetic or acquired bleeding disposition or anticoagulant factors deficiency.
9. Coagulation disorder with INR \>1.7 or use of new oral anticoagulants within 48 hours prior to symptom onset.
10. Platelet count \<50×10\^9/L.
11. Any active or recent bleeding (gastrointestinal, urinary tract bleeding, etc.), or previous parenchymal organ surgery or biopsy in the last 1 month.
12. Systolic blood pressure \>185 mmHg or diastolic blood pressure \>110 mmHg, refractory to treatment.
13. Known severe renal insufficiency with glomerular filtration rate \<30 ml/min or blood creatinine \>220 μmol/L (2.5 mg/dl).
14. Radiological confirmed evidence of mass effect or intracranial tumour (except small meningioma).
15. Anticipated life expectancy \<6 months due to advanced disease (e.g., malignancy, severe cardiopulmonary disease, etc.).
16. Women who are pregnant or breastfeeding.
17. Participation in other clinical trials.
18. Any condition that, in the judgment of the investigator, makes the patient unsuitable for this study or where this study may impose a significant risk to the patient (e.g., inability to understand and/or comply with study procedures and/or follow-up due to psychiatric disorders, cognitive or emotional impairment).

Where it's running

• Sun Yat-sen Memorial Hospital, Sun Yat-sen University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Yamei Tang — Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
• Study coordinator: Zhenhong Deng
• Email: dengzhh58@mail.sysu.edu.cn
• Phone: 86-20-81332619

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Short-Term outside-in nerve stimulation for acute ischemic stroke

  This trial tests whether a 5-day external trigeminal nerve stimulation given after stroke can help more patients recover better than a sham treatment.

  Recruiting Xidian University · Xi'an · NCT07911605

• Sevoflurane vs. Propofol for anesthesia in stroke patients undergoing clot-removal

  This study tests whether sevoflurane or propofol used for anesthesia during endovascular treatment of an acute ischemic stroke affects the final brain damage and recovery.

  Recruiting Phase 3 Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Barcelona · NCT07902791

• Safety of adding NRICM301 to standard care for adults with acute ischemic stroke

  This study tests whether adding NRICM301, a traditional Chinese medicine formula, to usual care is safe for adults with acute ischemic stroke.

  Recruiting En Chu Kong Hospital · New Taipei City · NCT07900503

• Intracranial Recanalization with LT3001 in Acute Ischemic Stroke

  This phase II study tests whether LT3001 given to adults with acute ischemic stroke can help reopen blocked brain arteries.

  Recruiting Phase 2 Lumosa Therapeutics Co., Ltd. · Taichung · NCT07890298

• Mobilisation After Endovascular Stroke Treatment

  This study checks whether moving around 12 hours after endovascular stroke treatment is as safe as moving around 24 hours for people with an acute ischemic stroke.

  Recruiting at 2 sites Karolinska Institutet · Tampere and 1 other locations · NCT07860333

• Endovascular therapy plus standard care vs standard care alone for distal and medium vessel strokes

  In people with acute ischemic stroke due to distal or medium vessel blockages, this study tests whether adding endovascular treatment to the usual medical care helps improve outcomes compared with medical care alone.

  Recruiting Hospital Universitari Vall d'Hebron Research Institute · Barcelona, Barcelona · NCT07843797

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.